中国药理学通报2023，Vol.39Issue(12)：2221-2224,4.DOI:10.12360/CPB202210041
母婴阻断中抗乙型肝炎病毒药物核苷(酸)类似物的治疗进展
Progress in treatment of anti-hepatitis B virus drug nucleoside analogues in preventing mother-to-child transmission
摘要
Abstract
Mother-to-child transmission of hepatitis B virus(HBV)is one of the main ways of transmission and the main cause of chronic hepatitis B after infection.Therefore,preven-ting mother-to-child transmission of HBV is particularly impor-tant in reducing the incidence of chronic hepatitis B.Currently,nucleoside(acid)analoids(Nas)used for mother-to-child blocking of HBV include lamivudine(LAM),tibivudine(LdT)and tenofovir fumarate(TDF).Propofol tenofovir fumarate(TAF)has also been used in pregnant chronic hepatitis B pa-tients.This paper summarizes the efficacy,safety and antiviral treatment indications and termination time of the above-men-tioned drugs in mother-to-child preventing to provide suggestions for the selection and rational application of mother-to-child pre-venting Nas.关键词
慢性乙型肝炎/母婴阻断/核苷(酸)类似物/疗效/安全性/治疗进展Key words
chronic hepatitis B/prevention of mother-to-child transmission/nucleoside analogues/efficacy/safety/treatment progress分类
医药卫生引用本文复制引用
郑洲松,黄燕,黄泽炳..母婴阻断中抗乙型肝炎病毒药物核苷(酸)类似物的治疗进展[J].中国药理学通报,2023,39(12):2221-2224,4.基金项目
国家科技重大专项(No 2018ZX10723203-004-003) （No 2018ZX10723203-004-003）
